Metagenomi, Inc.

MGX

Explore Our Financial Data > Companies > Emeryville, California Companies > Metagenomi, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
MGX
CIK0001785279
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
Website metagenomi.co
Phone(510) 871-4880
CEOBrian C. Thomas
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$22.33 million
Pre-Tax Income$-86.03 million
Net Income$-85.89 million
Net Income to Common$-85.89 million
EPS$-2.29
View All
Balance Sheet
Cash$25.31 million
Assets$196.95 million
Liabilities$59.17 million
Common Equity$137.78 million
Liabilities & Equity$196.95 million
View All
Cash Flow Statement
Net Income$-85.89 million
Cash From Operating Activities$-87.22 million
Cash From Investing Activities$82.79 million
Cash From Financing Activities$-306,000.00
Change in Cash$-4.74 million
View All
Calculations
NOPAT$-64.95 million
EBITDA$-91.49 million
Price to EarningsN/A
Price to Book$0.37
ROE-49.02%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET.

Article Link

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

Metagenomi Therapeutics, Inc. ( NASDAQ:MGX ) missed earnings with its latest first-quarter results, disappointing...

Article Link

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -2.52% and -68.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Cali

Article Link

Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +26.03% and -10.73%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Article Link